We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > oral treatment

News List

UK biotech gets grant for further trial of osteoarthritis drug pharmaphorum
February 21, 2019
UK biotech AKL Research and Development (AKLRD) has received a grant from a UK government-backed innovation body to develop its potentially “game changing” osteoarthritis drug.
FDA approves Pfizer's Xeljanz for ulcerative colitis pharmatimes
July 12, 2018
The FDA has approved Pfizer's Xeljanz (tofacitinib) for the treatment of moderately to severely active ulcerative colitis.
FDA approves Pfizer's Xeljanz for ulcerative colitis pharmatimes
July 06, 2018
The FDA has approved Pfizer's Xeljanz (tofacitinib) for the treatment of moderately to severely active ulcerative colitis.
Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless worldpharmanews
April 05, 2017
Findings from a post hoc analysis of the phase 3a SUSTAIN 2-4 trials demonstrated greater mean reductions in HbA1c and body weight with once-weekly semaglutide treatment compared to sitagliptin...